Campath Could Be Approved For Multiple Sclerosis By 2009, Genzyme Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Genzyme CEO Termeer predicts the approval process will take three to four years following the halting of a Phase II trial in MS because of safety concerns.